Filip Janku

List of Publications by Citations

146 papers	9,244 citations	46 h-index	95 g-index
156 ext. papers	11,097 ext. citations	6.7 avg, IF	6.31 L-index

#	Paper	IF	Citations
146	Autophagy as a target for anticancer therapy. *Nature Reviews Clinical Oncology*, **2011**, 8, 528-39	19.4	595
145	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. *Pharmacology & Therapeutics* , **2014**, 142, 164-75	13.9	520
144	Targeting the PI3K pathway in cancer: are we making headway?. *Nature Reviews Clinical Oncology*, **2018**, 15, 273-291	19.4	491
143	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. *Journal of Clinical Oncology*, **2015**, 33, 4032-8	2.2	424
142	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. *Clinical Cancer Research*, **2012**, 18, 6373-83	12.9	391
141	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. *Journal of Clinical Oncology*, **2012**, 30, 777-82	2.2	355
140	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. *Journal of Clinical Oncology*, **2015**, 33, 2753-62	2.2	295
139	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. *Molecular Cancer Therapeutics*, **2011**, 10, 558-65	6.1	281
138	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. *Cancer Discovery*, **2016**, 6, 154-65	24.4	269
137	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. *Cancer Research*, **2013**, 73, 276-84	10.1	221
136	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. *Clinical Cancer Research*, **2015**, 21, 730-8	12.9	215
135	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. *Nature Reviews Clinical Oncology*, **2010**, 7, 401-14	19.4	205
134	Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. *Science Translational Medicine*, **2014**, 6, 249ra111	17.5	202
133	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. *Cancer Discovery*, **2018**, 8, 184-195	24.4	198
132	Phosphatidylinositol 3-Kinase Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. *Journal of Clinical Oncology*, **2018**, 36, 1291-1299	2.2	190
131	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. *Cell Reports*, **2014**, 6, 377-87	10.6	186
130	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. *Cancer Research*, **2016**, 76, 3690-701	10.1	154

129	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. *PLoS ONE*, **2011**, 6, e22769	3.7	153
128	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. *Cancer Discovery*, **2016**, 6, 1352-1365	24.4	150
127	Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. *Clinical Cancer Research*, **2014**, 20, 4827-36	12.9	150
126	HER2/neu-directed therapy for biliary tract cancer. *Journal of Hematology and Oncology*, **2015**, 8, 58	22.4	149
125	Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. *Cancer Treatment Reviews*, **2017**, 59, 93-101	14.4	138
124	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 711-720	18.8	110
123	Novel therapeutic targets in non-small cell lung cancer. *Journal of Thoracic Oncology*, **2011**, 6, 1601-12	8.9	110
122	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. *Journal of Clinical Oncology*, **2016**, 34, 1764-71	2.2	102
121	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. *Investigational New Drugs*, **2018**, 36, 638-646	4.3	102
120	Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. *Cancer Discovery*, **2015**, 5, 64-71	24.4	101
119	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. *JAMA Oncology*, **2017**, 3, 509-515	13.4	97
118	Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. *Cancer Cell*, **2019**, 35, 738-751.e9	24.3	93
117	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. *Clinical Cancer Research*, **2018**, 24, 181-188	12.9	89
116	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. *Oncotarget*, **2013**, 4, 705-14	3.3	87
115	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. *Oncotarget*, **2015**, 6, 12809-21	3.3	77
114	BRAF mutations in advanced cancers: clinical characteristics and outcomes. *PLoS ONE*, **2011**, 6, e25806	3.7	72
113	PIK3CA mutations in advanced cancers: characteristics and outcomes. *Oncotarget*, **2012**, 3, 1566-75	3.3	71
112	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. *JCO Precision Oncology*, **2017**, 2017,	3.6	67

111	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials **2017**, 5, 100		67
110	Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. *Oncotarget*, **2014**, 5, 3012-22	3.3	67
109	Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma. *Journal of Clinical Oncology*, **2020**, 38, 3398-3406	2.2	65
108	Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. *Cancer*, **2012**, 118, 1422-8	6.4	65
107	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. *Molecular Cancer Therapeutics*, **2016**, 15, 1397-404	6.1	61
106	Response of histiocytoses to imatinib mesylate: fire to ashes. *Journal of Clinical Oncology*, **2010**, 28, e633-6	2.2	59
105	BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. *Oncotarget*, **2014**, 5, 3607-10	3.3	56
104	Erdheim-Chester disease: characteristics and management. *Mayo Clinic Proceedings*, **2014**, 89, 985-96	6.4	50
103	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. *Oncotarget*, **2014**, 5, 2349-54	3.3	50
102	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. *Molecular Cancer Therapeutics*, **2016**, 15, 2475-2485	6.1	49
101	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. *Oncotarget*, **2014**, 5, 11168-79	3.3	47
100	The mu opioid receptor: A new target for cancer therapy?. *Cancer*, **2015**, 121, 2681-8	6.4	46
99	Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. *Molecular Cancer Therapeutics*, **2016**, 15, 533-47	6.1	46
98	Phase 2 study of pembrolizumab in patients with advanced rare cancers **2020**, 8,		45
97	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. *Clinical Cancer Research*, **2017**, 23, 3657-3666	12.9	44
96	A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. *Clinical Cancer Research*, **2011**, 17, 6840-6	12.9	42
95	FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. *PLoS ONE*, **2014**, 9, e89388	3.7	42
94	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. *Journal of Clinical Oncology*, **2020**, 38, 1693-1701	2.2	40

93	Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?. *Expert Review of Molecular Diagnostics*, **2015**, 15, 1631-44	3.8	39
92	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. *Clinical Cancer Research*, **2017**, 23, 5648-5656	12.9	38
91	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. *Oncotarget*, **2017**, 8, 39254-39267	3.3	38
90	KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. *PLoS ONE*, **2012**, 7, e38033	3.7	38
89	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. *Oncotarget*, **2015**, 6, 26886-94	3.3	38
88	A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. *Cancer Chemotherapy and Pharmacology*, **2018**, 82, 407-418	3.5	37
87	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. *Oncotarget*, **2016**, 7, 67521-67531	3.3	36
86	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. *Molecular Cancer Therapeutics*, **2013**, 12, 2857-63	6.1	35
85	KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. *Melanoma Research*, **2005**, 15, 251-6	3.3	34
84	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. *Clinical Cancer Research*, **2020**, 26, 1237-1246	12.9	33
83	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. *Journal of Clinical Oncology*, **2020**, 38, 3294-3303	2.2	31
82	Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. *Oncologist*, **2020**, 25, e160-e169	5.7	31
81	Challenges and perspective of drug repurposing strategies in early phase clinical trials. *Oncoscience*, **2015**, 2, 576-80	0.8	29
80	Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. *Oncoscience*, **2016**, 3, 164-72	0.8	29
79	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. *Oncologist*, **2018**, 23, 1300-1309	5.7	28
78	Novel secondary somatic mutations in Ewing sarcoma and desmoplastic small round cell tumors. *PLoS ONE*, **2014**, 9, e93676	3.7	28
77	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. *Clinical Cancer Research*, **2020**, 26, 1924-1931	12.9	26
76	Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.. *Journal of Clinical Oncology*, **2019**, 37, 3014-3014	2.2	25

75	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. *Clinical Cancer Research*, **2021**, 27, 4491-4499	12.9	25
74	Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. *Journal of Thoracic Oncology*, **2013**, 8, e19-20	8.9	24
73	A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal. *Oncotarget*, **2013**, 4, 463-73	3.3	23
72	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. *Molecular Cancer Therapeutics*, **2018**, 17, 671-676	6.1	23
71	Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.. *Journal of Clinical Oncology*, **2018**, 36, 2002-2002	2.2	22
70	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. *Investigational New Drugs*, **2015**, 33, 177-86	4.3	20
69	Targeted therapies for advanced Ewing sarcoma family of tumors. *Cancer Treatment Reviews*, **2015**, 41, 391-400	14.4	20
68	Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. *Clinical Cancer Research*, **2012**, 18, 6356-63	12.9	20
67	Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. *Oncotarget*, **2013**, 4, 884-9	3.3	18
66	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. *Oncologist*, **2019**, 24, 219-228	5.7	17
65	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. *Scientific Reports*, **2017**, 7, 15963	4.9	17
64	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. *Journal of Hematology and Oncology*, **2019**, 12, 145	22.4	17
63	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. *Molecular Cancer Therapeutics*, **2019**, 18, 1149-1157	6.1	16
62	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. *Oncoscience*, **2017**, 4, 47-56	0.8	16
61	Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. *Clinical Cancer Research*, **2010**, 16, 4031-7	12.9	15
60	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. *Oncotarget*, **2013**, 4, 772-84	3.3	15
59	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. *Cancer Medicine*, **2016**, 5, 3437-3444	4.8	12
58	Intratumoral Injection of -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. *Clinical Cancer Research*, **2021**, 27, 96-106	12.9	12

57	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. *Clinical Cancer Research*, **2021**, 27, 2723-2733	12.9	12
56	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. *Investigational New Drugs*, **2015**, 33, 700-9	4.3	11
55	Multiple gene aberrations and breast cancer: lessons from super-responders. *BMC Cancer*, **2015**, 15, 442	4.8	11
54	Cell-free DNA as a novel marker in cancer therapy. *Biomarkers in Medicine*, **2015**, 9, 703-12	2.3	10
53	Characteristics and survival of patients with advanced cancer and p53 mutations. *Oncotarget*, **2014**, 5, 3871-9	3.3	10
52	Hormonal modulation of ESR1 mutant metastasis. *Oncogene*, **2021**, 40, 997-1011	9.2	10
51	Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. *Journal of Clinical Oncology*, **2016**, 34, e34-7	2.2	9
50	A tale of two histiocytic disorders. *Oncologist*, **2013**, 18, 2-4	5.7	9
49	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. *Scientific Reports*, **2016**, 6, 35448	4.9	9
48	Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. *Oncologist*, **2011**, 16, 327-35	5.7	8
47	PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.. *Journal of Clinical Oncology*, **2012**, 30, 10510-10510	2.2	8
46	Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. *JCO Precision Oncology*, **2018**, 2,	3.6	8
45	Bringing Blood-Based Molecular Testing to the Clinic. *Clinical Cancer Research*, **2016**, 22, 5400-5402	12.9	7
44	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. *Cancer*, **2019**, 125, 463-472	6.4	7
43	Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. *Cancers*, **2021**, 13,	6.6	7
42	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. *Investigational New Drugs*, **2015**, 33, 215-24	4.3	6
41	Advances on the BRAF Front in Colorectal Cancer. *Cancer Discovery*, **2018**, 8, 389-391	24.4	6
40	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. *Oncoscience*, **2014**, 1, 522-530	0.8	6

39	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. *Oncotarget*, **2014**, 5, 8937-46	3.3	6
38	Associations between the gut microbiome and fatigue in cancer patients. *Scientific Reports*, **2021**, 11, 5847	4.9	6
37	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. *Scientific Reports*, **2021**, 11, 3667	4.9	6
36	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory **2020**, 8,		5
35	Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. *Targeted Oncology*, **2013**, 8, 183-188	5	5
34	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. *Clinical Cancer Research*, **2020**, 26, 5579-5587	12.9	5
33	4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. *Bulletin Du Cancer*, **2004**, 91, E279-83	2.4	5
32	Castleman disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. *Journal of Medical Case Reports*, **2015**, 9, 45	1.2	4
31	RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients. *Journal of Cancer*, **2020**, 11, 3543-3550	4.5	4
30	The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.. *Journal of Clinical Oncology*, **2020**, 38, 3547-3547	2.2	4
29	Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.. *Journal of Clinical Oncology*, **2020**, 38, 3640-3640	2.2	4
28	Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. *Oncotarget*, **2018**, 9, 33258-33270	3.3	4
27	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. *Scientific Reports*, **2020**, 10, 3080	4.9	3
26	Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.. *Journal of Clinical Oncology*, **2020**, 38, 3590-3590	2.2	3
25	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. *Oncotarget*, **2017**, 8, 33796-33806	3.3	3
24	A novel method for liquid-phase extraction of cell-free DNA for detection of circulating tumor DNA. *Scientific Reports*, **2021**, 11, 19653	4.9	3
23	First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. *Investigational New Drugs*, **2021**, 39, 1348-1356	4.3	3
22	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. *JCO Precision Oncology*, **2019**, 3,	3.6	3

21	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. *Molecular Cancer Research*, **2021**, 19, 395-402	6.6	3
20	Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement. *Irish Journal of Medical Science*, **2011**, 180, 765-6	1.9	2
19	Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?. *Journal of Clinical Oncology*, **2012**, 30, 892-3	2.2	2
18	Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors **2019**,		2
17	Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.. *Journal of Clinical Oncology*, **2020**, 38, 2504-2504	2.2	2
16	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. *European Journal of Cancer*, **2021**, 155, 236-244	7.5	2
15	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.. *JCO Precision Oncology*, **2022**, 6, e2100197	3.6	2
14	Circulating tumor DNA-From bench to bedside. *Current Problems in Cancer*, **2017**, 41, 212-221	2.3	1
13	Liquid Biopsies Using Plasma Exosomal Nucleic Acids. *Oncoscience*, **2019**, 6, 296-297	0.8	1
12	A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.. *Journal of Clinical Oncology*, **2020**, 38, TPS3162-TPS3162	2.2	1
11	Single-arm study of bimiralisib in head and neck squamous cell carcinoma (HNSCC) patients (pts) harboring NOTCH1 loss of function (LOF) mutations.. *Journal of Clinical Oncology*, **2020**, 38, TPS6590-TPS6590	2.2	1
10	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. *Cancer*, **2021**, 127, 391-402	6.4	1
9	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. *Clinical Cancer Research*, **2021**, 27, 1247-1255	12.9	1
8	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). *Journal of Translational Medicine*, **2021**, 19, 13	8.5	1
7	Moving Precision Oncology Forward Amid Myths and Misconceptions. *JAMA Oncology*, **2018**, 4, 1788-1789	13.4	1
6	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. *Investigational New Drugs*, **2021**, 39, 1357-1365	4.3	0
5	Intratumor immunotherapy utilizing real time radiological image guidance: Early experience from a tertiary cancer center.. *Journal of Clinical Oncology*, **2020**, 38, e15223-e15223	2.2	
4	An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.. *Journal of Clinical Oncology*, **2020**, 38, 6085-6085	2.2	

3	Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of cancer therapy.. *Journal of Clinical Oncology*, **2020**, 38, 3533-3533	2.2
2	Incorporating Circulating Biomarkers into Clinical Trials **2020**, 233-247	
1	Phase I Trial of Dabrafenib and Pazopanib in Mutated Advanced Malignancies.. *JCO Precision Oncology*, **2018**, 2, 1-19	3.6